Elastic Flow-Control Stents
VascX is developing elastic flow-control stents as part of its patented platform for hemodialysis access — an endovascular flow-control option intended for high-flow AV access circuits, including high-flow fistulas, where excessive dialysis access flow contributes to cardiac burden.
For decades, endovascular stents in dialysis access have been deployed to do one thing: keep vessels open. They have treated stenosis, lined damaged segments, and preserved patency. A flow-control stent reverses that intent. Rather than maximizing flow through a narrowed segment, it is designed to introduce controlled flow into a segment that is delivering more flow than the access circuit needs.
What is an elastic flow-control stent?
An elastic flow-control stent is an endovascular device designed to introduce controlled access flow into an existing AV fistula, AV graft, or other access circuit. Conventional stents in dialysis access are typically placed to treat stenosis or maintain patency; a flow-control stent's geometry is intended instead to limit excessive access flow without occluding the access.
The elastic component is what differentiates VascX's approach. The stent is designed to flex enough to accept standard endovascular interventions, including thrombectomy, and to return to its calibrated flow-control profile afterward. The design intent is for flow-control to be a property the device adds to the access, not a constraint it imposes on the clinician.
Why high-flow fistulas matter
AV fistulas are widely considered the preferred hemodialysis access where anatomically feasible, in part because of their durability and patency. Some fistulas, however, mature to or develop dialysis access flows well above what dialysis requires. Excessive flow in a high-flow fistula is not a problem for the dialysis machine itself — but it is a continuous load on the heart.
That continuous load is associated with cardiac burden in some patients, including cardiac remodeling, pulmonary hypertension, and high-output heart failure in susceptible patients. For a deeper look at the underlying problem, see high-flow dialysis access and high-output heart failure and dialysis access.
Endovascular flow-control
Endovascular flow-control refers to reducing excessive dialysis access flow through a device placed inside the vessel, delivered via the vascular system rather than through open surgical revision. An elastic flow-control stent is one example: the device is intended to limit access flow from inside the access circuit, while preserving the access for ongoing hemodialysis.
The endovascular framing matters clinically because many of the patients most likely to benefit from access flow reduction already have established access circuits. An endovascular option means flow-control can be introduced into an existing circuit without recreating the access surgically. VascX's elastic flow-control stents are investigational; the company has not yet demonstrated their clinical performance and they are not cleared or approved by the U.S. Food and Drug Administration.
Access flow reduction and cardiac burden
The case for access flow reduction rests on the relationship between continuous AV access flow and the workload imposed on the heart. Excessive AV access flow may contribute to cardiac remodeling, pulmonary hypertension, and high-output heart failure in susceptible patients. Reducing access flow, when clinically warranted, is intended to reduce that cumulative cardiac burden.
Historically, access flow reduction in fistulas has been pursued surgically — banding and similar revision procedures — once cardiac or other complications appeared. An endovascular flow-control option could shift access flow reduction earlier in the patient pathway and away from open revision, though that potential is design intent, not yet demonstrated clinical performance. VascX makes no claim that its devices are proven to treat or prevent high-output heart failure, cardiac remodeling, pulmonary hypertension, hospitalization, mortality, or access failure.
Part of the VascX patented platform
VascX's elastic flow-control stents are one component of a broader patented platform for flow-control dialysis access. At the Vascular Access Society of the Americas (VASA), Dr. John Ross discussed the "VascX patented platform" and presented images of VascX's "elastic flow-control grafts" and "elastic flow-control stents." The graft and the stent are designed to address related but distinct clinical situations: a graft for new access creation where flow-control can be built in from the start, and a stent for existing high-flow AV access where flow-control needs to be introduced into the circuit.
Relationship to flow-control dialysis access
Elastic flow-control stents are part of the broader flow-control dialysis access category that VascX is building. Where elastic flow-control grafts incorporate controlled flow into a new access from the start, elastic flow-control stents introduce controlled flow into an existing access circuit. Together they are intended to make flow-control a design property of the access, rather than a reactive intervention that is only available after complications appear.
For more on the broader category and the VASA discussion, see flow-control dialysis access and the press release VascX flow-control platform highlighted at VASA.